Listed

Definium Therapeutics, Inc.

DFTXNasdaqCIK 1813814HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$75.1m, Q2 FY2026
Net income−$159.0m, Q2 FY2026
Definium Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m13.2Research and development, Q3 FY2023, three months to 2023-09-30$13.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure11.5Research and development, Q4 FY2023, three months to 2023-12-31$11.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-06, accession 0000950170-25-034176. Derived: 12-month figure less the 9-month figure.Report this figure11.7Research and development, Q1 FY2024, three months to 2024-03-31$11.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure14.6Research and development, Q2 FY2024, three months to 2024-06-30$14.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure17.2Research and development, Q3 FY2024, three months to 2024-09-30$17.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure21.8Research and development, Q4 FY2024, three months to 2024-12-31$21.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure23.4Research and development, Q1 FY2025, three months to 2025-03-31$23.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure29.8Research and development, Q2 FY2025, three months to 2025-06-30$29.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure31.0Research and development, Q3 FY2025, three months to 2025-09-30$31.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure33.5Research and development, Q4 FY2025, three months to 2025-12-31$33.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure41.5Research and development, Q1 FY2026, three months to 2026-03-31$41.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure48.7Research and development, Q2 FY2026, three months to 2026-06-30$48.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Operating income$m(21.6)Operating income, Q3 FY2023, three months to 2023-09-30−$21.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure(22.2)Operating income, Q4 FY2023, three months to 2023-12-31−$22.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-06, accession 0000950170-25-034176. Derived: 12-month figure less the 9-month figure.Report this figure(22.2)Operating income, Q1 FY2024, three months to 2024-03-31−$22.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure(24.5)Operating income, Q2 FY2024, three months to 2024-06-30−$24.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure(24.8)Operating income, Q3 FY2024, three months to 2024-09-30−$24.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure(32.5)Operating income, Q4 FY2024, three months to 2024-12-31−$32.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure(32.2)Operating income, Q1 FY2025, three months to 2025-03-31−$32.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(40.9)Operating income, Q2 FY2025, three months to 2025-06-30−$40.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure(45.7)Operating income, Q3 FY2025, three months to 2025-09-30−$45.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure(47.6)Operating income, Q4 FY2025, three months to 2025-12-31−$47.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure(59.2)Operating income, Q1 FY2026, three months to 2026-03-31−$59.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(75.1)Operating income, Q2 FY2026, three months to 2026-06-30−$75.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Interest expense$m0.3Interest expense, Q3 FY2023, three months to 2023-09-30$328.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure0.4Interest expense, Q4 FY2023, three months to 2023-12-31$439.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2025-03-06, accession 0000950170-25-034176. Derived: 12-month figure less the 9-month figure.Report this figure0.4Interest expense, Q1 FY2024, three months to 2024-03-31$434.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure0.5Interest expense, Q2 FY2024, three months to 2024-06-30$466.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure0.7Interest expense, Q3 FY2024, three months to 2024-09-30$727.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure0.7Interest expense, Q4 FY2024, three months to 2024-12-31$656.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure0.6Interest expense, Q1 FY2025, three months to 2025-03-31$602.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure2.3Interest expense, Q2 FY2025, three months to 2025-06-30$2.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure1.3Interest expense, Q3 FY2025, three months to 2025-09-30$1.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure1.3Interest expense, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:InterestExpense. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure1.2Interest expense, Q1 FY2026, three months to 2026-03-31$1.2m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure1.2Interest expense, Q2 FY2026, three months to 2026-06-30$1.2m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(17.9)Net income, Q3 FY2023, three months to 2023-09-30−$17.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure(23.9)Net income, Q4 FY2023, three months to 2023-12-31−$23.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-06, accession 0000950170-25-034176. Derived: 12-month figure less the 9-month figure.Report this figure(54.4)Net income, Q1 FY2024, three months to 2024-03-31−$54.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure(5.9)Net income, Q2 FY2024, three months to 2024-06-30−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure(13.7)Net income, Q3 FY2024, three months to 2024-09-30−$13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure(34.7)Net income, Q4 FY2024, three months to 2024-12-31−$34.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure(23.3)Net income, Q1 FY2025, three months to 2025-03-31−$23.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(42.7)Net income, Q2 FY2025, three months to 2025-06-30−$42.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure(67.3)Net income, Q3 FY2025, three months to 2025-09-30−$67.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure(50.4)Net income, Q4 FY2025, three months to 2025-12-31−$50.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure(77.1)Net income, Q1 FY2026, three months to 2026-03-31−$77.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(159)Net income, Q2 FY2026, three months to 2026-06-30−$159.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Diluted EPS$ per share(0.45)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figurenot reported(1.14)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure(0.26)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure(0.27)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figurenot reported(0.35)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(0.50)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure(0.78)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figurenot reported(0.71)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(1.44)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Basic EPS$ per share(0.45)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figurenot reported(1.14)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure(0.08)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure(0.18)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figurenot reported(0.27)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(0.50)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure(0.78)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.78 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figurenot reported(0.71)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(1.44)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure

Balance sheet

Cash and equivalents$655.3m, Q2 FY2026
Long-term debt$36.5m, Q2 FY2026
Shareholders' equity$918.7m, Q2 FY2026
Definium Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m118Cash and equivalents, Q3 FY2023, at 2023-09-30$117.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-02, accession 0000950170-23-058248.Report this figure99.7Cash and equivalents, FY2023, at 2023-12-31$99.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-06, accession 0000950170-25-034176.Report this figure252Cash and equivalents, Q1 FY2024, at 2024-03-31$252.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0000950170-24-055681.Report this figure243Cash and equivalents, Q2 FY2024, at 2024-06-30$243.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-13, accession 0000950170-24-095753.Report this figure295Cash and equivalents, Q3 FY2024, at 2024-09-30$295.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure274Cash and equivalents, FY2024, at 2024-12-31$273.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076742.Report this figure82.9Cash and equivalents, Q1 FY2025, at 2025-03-31$82.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure33.4Cash and equivalents, Q2 FY2025, at 2025-06-30$33.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure20.0Cash and equivalents, Q3 FY2025, at 2025-09-30$20.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure258Cash and equivalents, FY2025, at 2025-12-31$257.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure263Cash and equivalents, Q1 FY2026, at 2026-03-31$262.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure655Cash and equivalents, Q2 FY2026, at 2026-06-30$655.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Current assets$m120Current assets, Q3 FY2023, at 2023-09-30$120.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-058248.Report this figure104Current assets, FY2023, at 2023-12-31$103.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-06, accession 0000950170-25-034176.Report this figure255Current assets, Q1 FY2024, at 2024-03-31$255.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055681.Report this figure248Current assets, Q2 FY2024, at 2024-06-30$247.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0000950170-24-095753.Report this figure299Current assets, Q3 FY2024, at 2024-09-30$299.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure282Current assets, FY2024, at 2024-12-31$281.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076742.Report this figure222Current assets, Q1 FY2025, at 2025-03-31$221.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure189Current assets, Q2 FY2025, at 2025-06-30$189.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure216Current assets, Q3 FY2025, at 2025-09-30$215.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure419Current assets, FY2025, at 2025-12-31$419.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure381Current assets, Q1 FY2026, at 2026-03-31$380.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure1,092Current assets, Q2 FY2026, at 2026-06-30$1.09bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Total assets$m142Total assets, Q3 FY2023, at 2023-09-30$141.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0000950170-23-058248.Report this figure125Total assets, FY2023, at 2023-12-31$124.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-06, accession 0000950170-25-034176.Report this figure276Total assets, Q1 FY2024, at 2024-03-31$275.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0000950170-24-055681.Report this figure268Total assets, Q2 FY2024, at 2024-06-30$268.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0000950170-24-095753.Report this figure320Total assets, Q3 FY2024, at 2024-09-30$319.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure302Total assets, FY2024, at 2024-12-31$302.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-076742.Report this figure275Total assets, Q1 FY2025, at 2025-03-31$275.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure265Total assets, Q2 FY2025, at 2025-06-30$265.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure237Total assets, Q3 FY2025, at 2025-09-30$236.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure440Total assets, FY2025, at 2025-12-31$440.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure401Total assets, Q1 FY2026, at 2026-03-31$401.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure1,113Total assets, Q2 FY2026, at 2026-06-30$1.11bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Current liabilities$m31.2Current liabilities, Q3 FY2023, at 2023-09-30$31.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-058248.Report this figure32.2Current liabilities, FY2023, at 2023-12-31$32.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-06, accession 0000950170-25-034176.Report this figure65.3Current liabilities, Q1 FY2024, at 2024-03-31$65.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055681.Report this figure41.8Current liabilities, Q2 FY2024, at 2024-06-30$41.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0000950170-24-095753.Report this figure33.3Current liabilities, Q3 FY2024, at 2024-09-30$33.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure38.8Current liabilities, FY2024, at 2024-12-31$38.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076742.Report this figure30.5Current liabilities, Q1 FY2025, at 2025-03-31$30.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure38.0Current liabilities, Q2 FY2025, at 2025-06-30$38.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure65.4Current liabilities, Q3 FY2025, at 2025-09-30$65.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure66.7Current liabilities, FY2025, at 2025-12-31$66.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure81.1Current liabilities, Q1 FY2026, at 2026-03-31$81.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure157Current liabilities, Q2 FY2026, at 2026-06-30$157.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Total liabilities$m45.6Total liabilities, Q3 FY2023, at 2023-09-30$45.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0000950170-23-058248.Report this figure46.4Total liabilities, FY2023, at 2023-12-31$46.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-06, accession 0000950170-25-034176.Report this figure79.5Total liabilities, Q1 FY2024, at 2024-03-31$79.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0000950170-24-055681.Report this figure66.1Total liabilities, Q2 FY2024, at 2024-06-30$66.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0000950170-24-095753.Report this figure57.6Total liabilities, Q3 FY2024, at 2024-09-30$57.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure60.7Total liabilities, FY2024, at 2024-12-31$60.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-076742.Report this figure52.5Total liabilities, Q1 FY2025, at 2025-03-31$52.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure79.7Total liabilities, Q2 FY2025, at 2025-06-30$79.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure106Total liabilities, Q3 FY2025, at 2025-09-30$106.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure108Total liabilities, FY2025, at 2025-12-31$107.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure122Total liabilities, Q1 FY2026, at 2026-03-31$122.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure194Total liabilities, Q2 FY2026, at 2026-06-30$194.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Long-term debt$m14.1Long-term debt, Q3 FY2023, at 2023-09-30$14.1m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-11-02, accession 0000950170-23-058248.Report this figure14.1Long-term debt, FY2023, at 2023-12-31$14.1m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2024-02-28, accession 0000950170-24-021656.Report this figure14.2Long-term debt, Q1 FY2024, at 2024-03-31$14.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055681.Report this figure24.3Long-term debt, Q2 FY2024, at 2024-06-30$24.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-08-13, accession 0000950170-24-095753.Report this figure24.3Long-term debt, Q3 FY2024, at 2024-09-30$24.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure21.9Long-term debt, FY2024, at 2024-12-31$21.9m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2025-03-06, accession 0000950170-25-034176.Report this figure22.0Long-term debt, Q1 FY2025, at 2025-03-31$22.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure41.2Long-term debt, Q2 FY2025, at 2025-06-30$41.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure40.4Long-term debt, Q3 FY2025, at 2025-09-30$40.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure40.6Long-term debt, FY2025, at 2025-12-31$40.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-02-26, accession 0001193125-26-076742.Report this figure40.8Long-term debt, Q1 FY2026, at 2026-03-31$40.8m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure36.5Long-term debt, Q2 FY2026, at 2026-06-30$36.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure
Shareholders' equity$m96.0Shareholders' equity, Q3 FY2023, at 2023-09-30$96.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure78.1Shareholders' equity, FY2023, at 2023-12-31$78.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-076742.Report this figure196Shareholders' equity, Q1 FY2024, at 2024-03-31$196.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure202Shareholders' equity, Q2 FY2024, at 2024-06-30$202.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure262Shareholders' equity, Q3 FY2024, at 2024-09-30$262.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure241Shareholders' equity, FY2024, at 2024-12-31$241.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure223Shareholders' equity, Q1 FY2025, at 2025-03-31$222.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure185Shareholders' equity, Q2 FY2025, at 2025-06-30$185.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure131Shareholders' equity, Q3 FY2025, at 2025-09-30$130.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure332Shareholders' equity, FY2025, at 2025-12-31$332.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure279Shareholders' equity, Q1 FY2026, at 2026-03-31$278.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure919Shareholders' equity, Q2 FY2026, at 2026-06-30$918.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure

Cash flow

Operating cash flow−$52.8m, Q2 FY2026
Definium Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(16.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$16.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123391. Derived: 9-month figure less the 6-month figure.Report this figure(20.6)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$20.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-06, accession 0000950170-25-034176. Derived: 12-month figure less the 9-month figure.Report this figure(16.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$16.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure(20.0)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$20.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-07-31, accession 0000950170-25-100925. Derived: 6-month figure less the 3-month figure.Report this figure(17.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$17.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269596. Derived: 9-month figure less the 6-month figure.Report this figure(25.4)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$25.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure(29.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$29.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(29.6)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$29.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338066. Derived: 6-month figure less the 3-month figure.Report this figure(29.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$29.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269596. Derived: 9-month figure less the 6-month figure.Report this figure(43.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$43.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076742. Derived: 12-month figure less the 9-month figure.Report this figure(42.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$42.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure(52.8)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$52.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338066. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)110.68m, Q2 FY2026
Definium Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares29.3Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3029,296,333 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0000950170-23-058248.Report this figure38.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3138,077,251 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0000950170-24-055681.Report this figure38.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3038,576,394 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0000950170-24-095753.Report this figure39.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3039,720,007 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123391.Report this figure47.9Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3147,860,757 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0000950170-25-066387.Report this figure75.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3075,304,101 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-07-31, accession 0000950170-25-100925.Report this figure80.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3080,238,688 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure87.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3187,091,461 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure85.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3085,347,677 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure85.9Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3085,885,516 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269596.Report this figure109Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31108,790,941 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211989.Report this figure111Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30110,684,720 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure

Shares outstanding: 134.37mShares outstanding, period not labelled, at 2026-07-30134,366,950 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338066.Report this figure at Jul 30, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.